Literature DB >> 19844798

Screening mammography intervals among postmenopausal hormone therapy users and nonusers.

Tracy Onega1, Todd MacKenzie, Julia Weiss, Martha Goodrich, Linda Titus-Ernstoff.   

Abstract

BACKGROUND: The recent decline in US breast cancer incidence rates has been attributed to the marked reduction in use of postmenopausal hormone therapy (HT). An alternative explanation is that women who are not routinely seeking medical care to renew HT prescriptions may be less adherent to recommendations for mammographic screening. To investigate the latter possibility, we compared mammographic intervals according to HT use.
METHODS: Using data (1995-2007) from the New Hampshire Mammography Network (NHMN), a state-based mammography registry, we assessed mammographic intervals corresponding to HT use or nonuse among postmenopausal women. We used linear mixed effects models to assess whether the length of screening mammogram intervals differed according to HT use.
RESULTS: A total of 310,185 mammograms, representing 76,192 postmenopausal women and 319,353 person-years of screening, were included in the analysis. The median screening interval corresponding to HT use overall was 13.0 months (interquartile range: 12.4-15.1) and for nonuse was 13.1 (interquartile range: 12.4-15.8). Virtually, all screening mammograms occurred within a 2-year interval regardless of HT use or nonuse (98.5 and 98.1%, respectively).
CONCLUSIONS: Our findings indicate that screening mammography intervals are similar whether or not women are using HT. Thus, reduced utilization of screening mammography is unlikely to account for the decrease in breast cancer incidence seen soon after the WHI report.

Entities:  

Mesh:

Year:  2009        PMID: 19844798      PMCID: PMC3786216          DOI: 10.1007/s10552-009-9444-6

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  28 in total

1.  Postmenopausal hormone use, screening, and breast cancer: characterization and control of a bias.

Authors:  M M Joffe; C Byrne; G A Colditz
Journal:  Epidemiology       Date:  2001-07       Impact factor: 4.822

2.  Edinburgh trial of screening for breast cancer: mortality at seven years.

Authors:  M M Roberts; F E Alexander; T J Anderson; U Chetty; P T Donnan; P Forrest; W Hepburn; A Huggins; A E Kirkpatrick; J Lamb
Journal:  Lancet       Date:  1990-02-03       Impact factor: 79.321

3.  Type of postmenopausal hormone use and risk of breast cancer: 12-year follow-up from the Nurses' Health Study.

Authors:  G A Colditz; M J Stampfer; W C Willett; D J Hunter; J E Manson; C H Hennekens; B A Rosner; F E Speizer
Journal:  Cancer Causes Control       Date:  1992-09       Impact factor: 2.506

4.  Randomized study of mammography screening--preliminary report on mortality in the Stockholm trial.

Authors:  J Frisell; G Eklund; L Hellström; E Lidbrink; L E Rutqvist; A Somell
Journal:  Breast Cancer Res Treat       Date:  1991-03       Impact factor: 4.872

5.  Update of the Swedish two-county program of mammographic screening for breast cancer.

Authors:  L Tabàr; G Fagerberg; S W Duffy; N E Day; A Gad; O Gröntoft
Journal:  Radiol Clin North Am       Date:  1992-01       Impact factor: 2.303

6.  Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study.

Authors:  Per-Henrik Zahl; Bjørn Heine Strand; Jan Maehlen
Journal:  BMJ       Date:  2004-03-10

7.  Mammographic screening and mortality from breast cancer: the Malmö mammographic screening trial.

Authors:  I Andersson; K Aspegren; L Janzon; T Landberg; K Lindholm; F Linell; O Ljungberg; J Ranstam; B Sigfússon
Journal:  BMJ       Date:  1988-10-15

8.  Breast cancer and hormone-replacement therapy in the Million Women Study.

Authors:  Valerie Beral
Journal:  Lancet       Date:  2003-08-09       Impact factor: 79.321

9.  National use of postmenopausal hormone therapy: annual trends and response to recent evidence.

Authors:  Adam L Hersh; Marcia L Stefanick; Randall S Stafford
Journal:  JAMA       Date:  2004-01-07       Impact factor: 56.272

10.  Breast cancer after use of estrogen plus progestin in postmenopausal women.

Authors:  Rowan T Chlebowski; Lewis H Kuller; Ross L Prentice; Marcia L Stefanick; JoAnn E Manson; Margery Gass; Aaron K Aragaki; Judith K Ockene; Dorothy S Lane; Gloria E Sarto; Aleksandar Rajkovic; Robert Schenken; Susan L Hendrix; Peter M Ravdin; Thomas E Rohan; Shagufta Yasmeen; Garnet Anderson
Journal:  N Engl J Med       Date:  2009-02-05       Impact factor: 91.245

View more
  3 in total

1.  Screening mammography use among current, former, and never hormone therapy users may not explain recent declines in breast cancer incidence.

Authors:  Diana S M Buist; Rod Walker; Erin J Aiello Bowles; Patricia A Carney; Stephen H Taplin; Tracy Onega; Karla Kerlikowske; Walter Clinton; Diana L Miglioretti
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-02-01       Impact factor: 4.254

2.  Age-related variation in the relationship between menopausal hormone therapy and the risk of dying from breast cancer.

Authors:  Kerryn W Reding; David R Doody; Anne McTiernan; Li Hsu; Scott Davis; Janet R Daling; Peggy L Porter; Kathleen E Malone
Journal:  Breast Cancer Res Treat       Date:  2010-09-29       Impact factor: 4.872

3.  Changes in invasive breast cancer and ductal carcinoma in situ rates in relation to the decline in hormone therapy use.

Authors:  Ghada N Farhat; Rod Walker; Diana S M Buist; Tracy Onega; Karla Kerlikowske
Journal:  J Clin Oncol       Date:  2010-11-08       Impact factor: 44.544

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.